Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults
NCT06182124Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pneumococcal disease (6 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prespecified local reactions at 7 days, Percentage of participants reporting prespecified systemic events at 7 days and 3 more. Started Dec 2023; status: completed.
02
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06182124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182124.